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(Enzyme-linked immunosorbent assay, ELISA)法检测血清及瘤组织中肿瘤细胞凋亡相
关因子血小板源性生长因子-BB(Platelet-derived growth factor-BB, PDGF-BB)、血管内

















(Cysteinyl aspartate-specific proteinase-3, Caspase-3)、含半胱氨酸天冬水解酶-7 (Cysteinyl
aspartate-specific proteinase-7, Caspase-7)、含半胱氨酸天冬水解酶-9 (Cysteinyl aspartate-
specific proteinase-9, Caspase-9)、核转录因子-КB(Nuclear Factor kappa B, NF-КB)、蛋
白激酶 B(Akt)及磷酸化蛋白激酶 B(pAkt)等的表达水平；运用实时荧光定量-聚合酶链
式反应(Realtime fluorescence quantitative polymerase chain reaction, RTFQ-PCR)法检测
肿瘤组织中细胞凋亡相关因子 Caspase-3、Caspase-7、Caspase-9、NF-КB、B淋巴细胞












联合治疗组肿瘤组织中 NF-КB、Akt及 pAkt蛋白表达和 Bcl-2及 Bcl-XL基因表达较单
一化疗组呈现出被下调的趋势；肿瘤组织中 Caspase-3、Caspase-7、Caspase-9表达较
单一化疗组增加。且以 SLBZP高剂量+CTX组上述作用最为显著。



















Background: Hepatocellular carcinoma (HCC) is one of the common malignant tumors
in China, with a high degree of malignancy, short survival time, easy recurrence and poor
prognosis. Hepatocellular carcinoma is currently the 3rd leading cause of cancer death in the
world. While the mortality of hepatic carcinoma ranks second, just next to lung cancer, in
China. At present, chemotherapy as an important method for the treatment of liver cancer is
easy to cause adverse reactions such as leukopenia, abnormal liver function, nausea and
vomiting, loss of appetite, diarrhea, constipation and abdominal pain. And Chinese medicine
can reduce the side effects of chemotherapy in patients, with increased treatment effects and
reduce toxicity. It has been found that, Shen-Ling-Bai-Zhu Powder can relieve unwell
symptoms and improve quality of life, in patients with hepatocellular carcinoma receiving
chemotherapy. However, the related mechanism is still incompletely clear, and further study
on the mechanism is necessary.
Aim: To investigate the effects of SLBZP alone and in combination with Cytoxan (CTX)
on tumor growth, malignant cell apoptosis and Akt/Nuclear Factor kappa B (NF-КB)
signaling in a murine chemotherapeutic model of hepatocellular carcinoma (HCC).
Methods: Sixty-four Kunming mice were subcutaneously injected with suspension of H22
hepatocellular carcinoma cells (2×107/mL) into the right anterior armpit. All mice were
received intraperitoneal injection with cytoxan (CTX, 200mg/kg) to establish the
chemotherapeutic animal model of HCC. Mice were then randomized into eight study
groups. One was treated with CTX (20mg/kg) alone (positive control), one with physiologic
saline (untreated, negative control), three with SLBZP (6.00, 3.00, 1.50 g/kg), and three with
SLBZP (6.00, 3.00, 1.50g/kg) plus CTX (0.02g/kg). Mice were allowed free access to food
and water. The SLBZP (H), SLBZP (M) and SLBZP (L) treated groups received their
treatments by intragastric administration of SLBZP aqueous solution once a day. The three
combined treatment groups were treated with SLBZP as described above, plus















with CTX every 2 days. Finally, the untreated negative control group was injected with 0.2
mL/10g Sodium Chloride Physiological Solution as per the CTX alone group. All groups
were treated for 14 days. Tumor size, histology and serum or tissue levels and/or mRNA
expression of PDGF-BB, VEGF, Ang-1, Ang-2, Caspase-3, Caspase-7, Caspase-9, NF-КB,
B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-extra large (Bcl-XL), Akt and phosphorylated
Akt expression were documented at the end of treatment.
Results: Tumor inhibitory ratios in CTX alone, SLBZP (H), SLBZP (H) plus CTX, and
SLBZP (M) plus CTX were 52.39%, 45.84%, 58.41% and 52.77%, respectively. Tumor cell
density was decreased in all treated groups but most apparent in the SLBZP (H) plus CTX
group. Electron microscopic evidence of apoptosis was also most apparent in this group.
Compared to untreated negative controls, the protein expression of PDGF-BB, VEGF, Ang-1,
Ang-2, NF-КB, and XIAP were obviously lower in all treated groups. And the the protein
expression of Caspase-3, Caspase-7 and Caspase-9 in all treated groups were obviously
higher than those in negative controls. But their downstream signaling proteins and
anti-apoptotic markers were lowest and pro-apoptotic markers highest in SLBZP (H) plus
CTX treated mice.
Conclusion: In this chemotheraptice animal model of HCC, SLBZP was most
efficacious as adjunctive therapy and appears to act by inhibiting tumor growth promoters
and anti-apoptotic proteins while enhancing pro-apoptotic proteins.
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SLBZP Shen-Ling-Bai-Zhu Powder 参苓白术散
HCC Hepatocellular carcinoma 肝细胞癌
PDGF-BB Platelet-derived growth factor-BB 血小板源性生长因子-BB
VEGF Vascular endothelial growth factor 血管内皮生长因子
Ang-1 Angiogenin-1 血管生成素-1
Ang-2 Angiogenin-2 血管生成素-2
NF-КB Nuclear Factor kappa B 核转录因子-КB
Caspase-3 Cysteinyl aspartate-specific proteinase-3 含半胱氨酸天冬水解酶-3
Caspase-7 Cysteinyl aspartate-specific proteinase-7 含半胱氨酸天冬水解酶-7
Caspase-9 Cysteinyl aspartate-specific proteinase-9 含半胱氨酸天冬水解酶-9





WB Western blotting 蛋白印迹法
HE Hematoxylin-eosin staining 苏木精-伊红染色法

























































(Vascular endothelial growth factor, VEGF)、血小板源性生长因子(Plateled-derived




































(The Laboratory Animal Administration and Ethics Committee of Xiamen University)









































































磷酸盐缓冲液(Phosphate Buffered Saline，以下简称“PBS”)稀释，配制成 H22肝癌细





低剂量加 CTX组，共 8组，每组 8只。造模成功 24h后开始给药：分组后称重并记
录，按照小鼠体重给药，模型组以 0.9%生理盐水 0.2mL/10g 进行灌胃，1次/d，并
以 0.9%生理盐水 0.2mL/10g 进行腹腔注射，1 次 /2d；CTX 组以 0.9%生理盐水
0.2mL/10g进行灌胃，1次/d，并以 20mg/kg CTX注射液 0.2mL/10g进行腹腔注射，
1次/2d；SLBZP高中低剂量组分别以 3.00g/mL、1.50g/mL、0.75g/mL中药 0.2mL/10g
进行灌胃，1次/d，以 0.9%生理盐水 0.2mL/10g进行腹腔注射，1次/2d；SLBZP 高
中低剂量加 CTX 组分别以 3.00g/mL、1.50g/mL、0.75g/mL 中药 0.2mL/10g 进行灌
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